1618PPrognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) treatment in patients (pts) with advanced gastrointestinal stromal tumor (GIST)
Cho, H, Ryu, M-H, Chae, H, Lee, S M, Park, Y, Kim, K-H, Kim, C W, Kim, B S, Yoo, M-W, Ma, J, Beck, M Y, Kim, M, Kang, Y-KVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy299.017
Date:
October, 2018
File:
PDF, 75 KB
english, 2018
File converter
More search results
More benefits 
